

Concerning the plausibility of the findings reported in 'Prenatal exposure to glycol ethers and cryptorchidism and hypospadias a nested case-control study' by Smet and Kelsey: authors' response

Reply Letter to Smet and Kelsey: *Concerning the plausibility of the findings reported in "Prenatal exposure to glycol ethers and cryptorchidism and hypospadias: a nested case-control study", Warembourg et al, Occup Environ Med 2018;75:59-65*

Warembourg C¹, Multigner L¹, and Garlantézec R^{1,2}.

¹ Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000, Rennes, France

² Service de Santé Publique et d'Epidemiologie, Centre Hospitalo-Universitaire de Rennes, F-35033, Rennes, France

Corresponding author:

Full name: Dr Charline Warembourg

Postal address: UMR Inserm 1085 Irset – 9 Avenue du Prof. Léon Bernard, 35000 Rennes, France

Email: charline.warembourg@gmail.com

Conflict of interest:

None to declare

We read with attention the letter from Smet and Kelsey discussing the interpretation of our findings. Smet and Kelsey¹ questioned the validity of our findings regarding the high detection rate of methoxyacetic acid (MAA) we observed in our population despite the restriction in use of its precursors in Europe. First, human biomonitoring studies on glycol ether (GE) exposure in the non-occupational context are very few but other recent studies have also reported a high detection rate of MAA in the European general population in 2007–2009: MAA was detected in 99% and 100% of urine samples with a median concentration of 0.05 mg/L and 0.11mg/L in a German² and a French population,³ respectively. Second, regarding the sources of exposure to diethylene glycol monomethyl ether (DEGME) and triethylene glycol monomethyl ether (TEGME) as potential precursors of MAA detected in our study population, the period of recruitment (2002–2006) of the pregnant women included in our study should be considered. The references given by Smet and Kelsey are not reflecting the usage at the time of the study. Indeed, DEGME is no longer used in consumer products since 2010 (at least without a concentration exceeding 0.1% by weight) but was previously used in paints and cleaning agents as assessed by the European chemicals agency⁴ and the French agency for environmental and occupational safety.⁵ Nowadays, as Smet et al said, TEGME is mainly use in hydraulic fluids but the reference they cited reported additional usages in consumer products such as in coatings, adhesives or inks, and that 'other release to the environment is likely to occur from [...] indoor use (eg, machine wash liquids/detergents, automotive care products, paints and coating or adhesives, fragrances and air fresheners).⁶ Finally, we would like to highlight that each of these two GE (DEGME and TEGME) are manufactured or imported in 10000 to 100000 tons per annum in Europe.^{6,7} Smet and Kelsey consider that the MAA we measured could not come from GE exposures; however, they did not provide any alternative exposure source that may explain the detection of MAA in urine. To our knowledge, there are no other compounds than GE as precursors of MAA.

As a second limitation, Smet and Kelsey indicate that the prevalence of male genital anomalies in our study is low. As we acknowledged in the discussion section of our article, the prevalence of male genital anomalies (especially cryptorchidism) is highly dependent of its definition (ie, the inclusion or exclusion of minor cases).⁸ In our study, 1.9% of boys were diagnosed with cryptorchidism at birth (excluding cases with testis in high scrotal position) and 0.4% with hypospadias. Comparing with data published by Boisen et al (original reference used by Skakkebaek), the prevalence of cryptorchidism after exclusion of cases with testis in high scrotal position is similar to the one we reported: 1.2% in Finland and 2.1% in Denmark. For hypospadias, prevalence in the EDEN (Etude des déterminants pré et postnataux du développement et de la santé de l'enfant) and PELAGIE (Perturbateurs endocriniens: étude longitudinale sur les anomalies de la grossesse, l'infertilité et l'enfance) cohorts are in accordance with existing prevalence data.⁹ In any case, it is known that the toxic effect of GE is caused by their alkox acid metabolites—in particular, MAA which is a known testicular toxicant—and ignoring the parent compound did not question our conclusion. Additional human biomonitoring studies would be important to assess current exposure level and evaluate the source of GE metabolites. Such studies will help to correctly perform a risk assessment evaluation and potentially provide recommendations to limit exposure of pregnant women. In addition, even if the European population is no longer being exposed to MAA, our results are of concern for non-European countries where precursors of MAA are not regulated.

References:

1. Smet K, Kelsey J. Plausibility of the findings reported in 'Prenatal exposure to glycol ethers and cryptorchidism and hypospadias: a nested case– control study. *Occup Environ Med* 2018. doi:10.1136/oemed-2018-105346. [Epub ahead of print 14 Sept 2018].
2. Fromme H, Nitschke L, Boehmer S, et al. Exposure of German residents to ethylene and propylene glycol ethers in general and after cleaning scenarios. *Chemosphere* 2013;90:2714–21.
3. Nisse C, Labat L, Thomas J, et al. Caractérisation de l'exposition aux éthers de glycol d'un échantillon de population générale du Nord–Pas-de-Calais par biométrie urinaire. *Toxicol Anal Clin* 2017;29:418–40.
4. European Chemicals Agency. Annex XVII to REACH – Conditions of restriction of DEGME. <https://echa.europa.eu/documents/10162/c0b7baea-d2d6-4fa5-86b8-c322ab573d8f> (accessed 23 Jul 2018).
5. AFSSET, 2003. Les éthers de glycol - Synthèse des connaissances sur les expositions de la population générale en France, 2008 <https://www.anses.fr/fr/system/files/CHIM2003et0016Ra-3.pdf> (accessed 23 Jul 2018).
6. European Chemicals Agency. Brief profile for TEGME. <https://echa.europa.eu/fr/brief-profile/-/briefprofile/100.003.602> (accessed 23 Jul 2018).
7. European Chemicals Agency. Brief profile for DEGME. <https://echa.europa.eu/fr/substance-information/-/substanceinfo/100.003.551> (accessed 23 Jul 2018).
8. Boisen KA, Kaleva M, Main KM, et al. Difference in prevalence of congenital cryptorchidism in infants between two Nordic countries. *Lancet* 2004;363:1264–9.
9. Springer A, van den Heijkant M, Baumann S. Worldwide prevalence of hypospadias. *J Pediatr Urol* 2016;12:152. e1–7